Epidermal growth factor receptor (EGFR) gene mutations are the most common targetable genomic drivers of non-small cell lung cancer (NSCLC). EGFR Exon 20 insertions (EGFR Ex20Ins) which comprises of 4-10% of EGFR mutations is the third most common type of EGFR mutation in NSCLC. With conventional TKIs having poor efficacy in a majority of EGFR Ex20Ins subtypes, chemotherapy has remained the preferred treatment option. However, with market opportunity of about 20-30K new patients per year, many innovators are developing novel inhibitors that can be considered as putative candidates. Here in this digest we highlight the recent positive results reported in this space